The potential of adoptive transfer of γ9δ2 T cells to enhance blinatumomab’s antitumor activity against B-cell malignancy

Blinatumomab, a bispecific T cell engager (BiTE) antibody targeting CD19 and CD3ε, can redirect T cells toward CD19-positive tumor cells and has been approved to treat relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). However, chemotherapeutic regimens can severely reduce T cells’...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yun-Hsiang, Wang, Yun, Liao, Cheng-Hao, Hsu, Shu-Ching
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195997/
https://www.ncbi.nlm.nih.gov/pubmed/34117317
http://dx.doi.org/10.1038/s41598-021-91784-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195997/
https://www.ncbi.nlm.nih.gov/pubmed/34117317
http://dx.doi.org/10.1038/s41598-021-91784-1

Ejemplares similares